| Subject: | FDA Issues Safety Alert Regarding Zyprexa |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 22 Feb 2005 - 10:00 am |
| The FDA and the Eli Lilly and Company, have issued a safety alert regarding name confusion and dispensing errors concerning Zyprexa (olanzapine) and Zyrtec (cetirizine HCI). Zyprexa is an atypical antipsychotic prescribed for schizophrenia and bipolar I disorder, and Zyrtec is an antihistamine prescribed for allergic rhinitis and chronic urticaria. Eli Lilly and Company reports notification of instances where Zyprexa has been incorrectly dispensed as Zyrtec and where Zyrtec has been incorrectly... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|